GeoVax Labs Inc. is a biotechnology company developing human vaccines for HIV/AIDS and other infectious diseases. The company announced today that it has elected Steven Antebi and David A. Dodd to its board of directors. These appointments bring the number of board members to eight, five of whom are considered independent.
Since 1993, Mr. Antebi has been the president and chairman of the board of Maple Capital Management, an equity fund focused on investments in North America. He is also president and CEO of Galileo Partners LLC and president of Blue and Gold Enterprises Inc. These funds invest in registered direct investments, PIPE transactions, private placements and open market equity transactions. Prior to that, he served in various senior positions at Bear Stearns. Since 2009, Mr. Antebi has served as chairman of the board of Epinex Diagnostics and he has also served as a member of the board of governors of Cedars Sinai Hospital. All together, Mr. Antebi has nearly 30 years of financial industry expertise and experience in business development and management in the healthcare, technology and interactive media industries.
Mr. Dodd is the CEO of RiversEdge BioVentures, an investment and advisory firm focused on life sciences and pharmaceuticals, which he founded in 2009. He has more than 35 years of executive experience in the healthcare industry. From December 2007 to June 2009, Mr. Dodd was president, CEO and chairman of BioReliance Corporation, a company that provided biological safety testing, viral clearance testing, genetic and mammalian technology testing and laboratory animal diagnostic services testing. From October 2006 to April 2009, he served as non-executive chairman of Stem Cell Sciences PLC. Before that, Mr. Dodd served as president, CEO and director of Serologicals Corporation. This followed his five-year stint as president and CEO of Solway Pharmaceuticals and chairman of its subsidiary, Unimed Pharmaceuticals.
Geovax’s chairman of the board, Don Hildebrand, commented on the appointments, “Steven Antebi and David Dodd bring a tremendous amount of experience and innate ability to GeoVax. Their knowledge of business development and management as well as of the healthcare field is extraordinary, and we expect to rely on their professional acumen, experience and insights into capital formation as we work to accelerate our HIV/AIDS vaccine programs.”